The company is focused on identifying, assessing, and supporting selected private investment opportunities, with an emphasis on strategic research, market analysis, and long-term value creation.
Tracking the technologies shaping the next decade – from AI infrastructure and autonomous systems to biotechnology, space, and frontier markets.
Typewriter emerged from stealth with a $56M Series A to commercialize retrotransposon-based whole-gene insertion, targeting in vivo CAR-T and genetic liver disease. Non-human primate data arrives late 2026.
AeroVironment’s $464.8 million E-HEL award moves the 30 kW LOCUST X3 laser from prototype to production — the first directed-energy system in US military history to cross that line, and a signal that laser C-UAS economics have finally won.
Gridsight raised a $26M Series B led by Insight Partners to scale AI grid-capacity software. The platform doubled household solar export and unlocked 600+ MW on an existing network.
Crusoe closed a $3B round at a $30B valuation, anchored by a $13B Jane Street GPU contract. The energy-first neocloud model just got repriced.
Space domain awareness is becoming the traffic control layer of the commercial orbit economy. Inside the 2026 funding wave, the shift to AI threat detection, and who owns the catalog.
Biotech & Health The First RAS-Targeted Pancreatic Cancer Drug Just Changed the Math RASONQUE (daraxonrasib) is the first approved drug to hit RAS directly, the driver behind 90% of pancreatic tumours. In RASolute 302 it doubled median survival. Then came the $39,800-a-month list price. We assess
RASONQUE (daraxonrasib) is the first approved drug to hit RAS directly, the driver behind 90% of pancreatic tumours. In RASolute 302 it doubled median survival. Then came the $39,800-a-month list price. We assess the clinical event against the commercial bet.
Humanoids crossed from demo to deployment, but the evidence base is mostly vendor-authored. Agility's SPAC is about to price the gap for the first time.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
